Growth Metrics

Tg Therapeutics (TGTX) Shares Outstanding (Diluted Average) (2020 - 2025)

Tg Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $161.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $161.4 million for Q4 2025, up 0.67% from a year ago — trailing twelve months through Dec 2025 was $161.4 million (up 0.67% YoY), and the annual figure for FY2025 was $161.4 million, up 0.67%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $161.4 million at Tg Therapeutics, roughly flat from $162.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TGTX hit a ceiling of $162.1 million in Q3 2025 and a floor of $4.4 million in Q3 2023.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $134.5 million (2022), compared with a mean of $111.7 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 96.76% in 2023 and later soared 3568.33% in 2024.
  • Tg Therapeutics' Shares Outstanding (Diluted Average) stood at $132.4 million in 2021, then grew by 2.25% to $135.3 million in 2022, then plummeted by 95.16% to $6.6 million in 2023, then skyrocketed by 2346.63% to $160.3 million in 2024, then increased by 0.67% to $161.4 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $161.4 million (Q4 2025), $162.1 million (Q3 2025), and $15.8 million (Q2 2025) per Business Quant data.